Contact this trialFirst, we need to learn more about you.
Dopamine Receptor 1 Partial Agonist
Dopamine Receptor Agonist for Schizophrenia
Recruiting0 awardsPhase 1 & 2
Stony Brook, New York
This trial will test whether CVL-562, a dopamine 1 partial agonist, affects working memory in patients with early episode schizophrenia. The goal is to establish neuroimaging biomarkers of the Dopamine Receptor 1/Dopamine Receptor 5 Family target engagement to accelerate development of D1R/D5R agonists in humans to treat cognitive impairments in schizophrenia.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.